Biotech News

Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King

Cingulate Inc. (CING)Cingulate Inc.Company update

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products, announced today that Chairman and CEO Shane J. Schaffer has provided an update on the regulatory progress of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).

Related news

Cingulate Inc.

Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence. CTx-1301 ADHD Candidate CTx-1301 is a...

Recent company news

Stock data

Close
5.26 USD
Market cap
54.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States